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WS16.1 Development of a competitive ELISA for the detection of the
Burkholderia cenocepacia siderophore, ornibactin
N. Whelan1, M. Callaghan1, S. Doyle2. 1Institute of Technology Tallaght, Dublin,
Ireland; 2National University of Ireland Maynooth, Co. Kildare, Ireland
The acquisition of iron is critical for the survival of pathogenic bacteria including the
cystic ﬁbrosis (CF) pathogen B. cenocepacia. Siderophores are low molecular mass
iron chelators secreted by bacteria in order to solubilise and internalise ferric iron.
Ornibactin is the most abundant of four siderophores produced by B. cenocepacia
and is pivotal to the virulence of this opportunistic pathogen. An accurate method
of quantifying this important virulence factor will facilitate both pathogenesis
studies and the development and evaluation of therapies targeting iron acquisition.
Ornibactin was extracted and puriﬁed from B. cenocepacia iron-depleted cultures
and identiﬁed using reverse-phase HPLC and LC-MS analysis. Puriﬁed ornibactin
was then conjugated to the carrier protein BSA using photo-activation chemistry.
Resultant polyclonal antibodies against the ornibactin-conjugate were raised in
rabbits and the presence of serum antibodies to both ornibactin and ferric-ornibactin
conﬁrmed using immunoblot and Western blot analysis. A competitive ferric-
ornibactin ELISA was then developed by coating ELISA plates with a second
ornibactin-BSA conjugate to which the positive rabbit sera and ornibactin positive
sample compete for binding. Bound antibodies are detected using an anti-rabbit
HRP conjugate which catalyses a colorimetric reaction. The linear range of the
ELISA occurs between 0 and 500 ng/ml indicating an extremely sensitive assay. The
ferric-ornibactin competitive ELISA is currently under evaluation for the detection
of ferric-ornibactin in a range of clinical specimens.
WS16.2 Highly multiplexed molecular detection of CF lung infections
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Objectives: Culture-based detection of micro-organisms causing CF lung infection
is slow, labour intensive and may overlook fastidious or slow-growing pathogens.
This may hinder prompt and directed antibiotic treatment of pulmonary exacerba-
tions. We aimed to develop a highly multiplexed molecular diagnostic assay for the
simultaneous detection of bacteria, fungi and viruses directly from sputum without
prior culture.
Methods: Unique primer and probe sets compatible with an existing biochip array
platform (Evidence Investigator, Randox Laboratories Ltd) were designed to detect
120 species common to CF lung infections and to identify them to the species
or genus level as judged clinically relevant. Primers and probes were tested for
sensitivity and speciﬁcity in detecting multiple target isolates before trialling with
clinical sputum samples. Real-time PCR assays, culture data and next generation
sequencing were used as comparator technologies.
Results: Target speciﬁcities and sensitivities were conﬁrmed for all primer designs
and a high number of primer/probe sets were successfully trialled with sputum
samples. Sensitivities and speciﬁcities of 90–100% and 99–100%, respectively, were
achieved with clinical samples.
Conclusion: Based on multiplex PCR coupled to biochip array technology, we have
developed a unique multiplex molecular diagnostic assay tailored towards the direct
detection and identiﬁcation of a comprehensive proﬁle of agents contributing to CF
lung infection. Speciﬁcities and sensitivities indicate that the assay format is highly
suitable for this application and full clinical trialling is planned.
Funding: KTP between QUB, Randox Laboratories Ltd and TSB.
WS16.3 Rethinking Pseudomonas aeruginosa (PA) lung infection:
using molecular microbiology rather than culture and
antibodies
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Objective: We have revisited the adopted deﬁnition of the initial and persistent
P. aeruginosa (PA) lung infection in CF patients by combining genomics, molecular
microbiology and clinical data.
Methods: Clinical isolates of PA have been systematically collected for 10 years
from early infection stages in Copenhagen CF children and young adults. Based on
clinical characterization more than 500 isolates from 41 patients were chosen for
genome sequencing.
Results: More than 75% of all CF patients were infected with the same clone-type
during the entire collection period, despite intensive antibiotic therapy and although
the bacteria were eradicated from the sputum at the next microbiology examination.
Four types of infection patterns dominated 1) same persistent clone type, 2) same
persistent clone type with single invaders, 3) several co-existing clone types or 4)
clone replacement.
Conclusion: Today the deﬁnition of intermittent or chronic PA lung infection is
based on clinical and laboratory ﬁndings, e.g. intermittent colonisation: PA in
<50% of sputum samples or chronic infection: PA in 50% of sputum samples
within one year, respectively. In addition increasing ELISA or precipitating anti-
bodies against PA is a predictor of infection in some centres. Molecular methods,
however, show that the majority of patients are infected persistently with the same
clone type from the very beginning. Most CF patients are therefore either non-
colonised or chronically infected; this needs to be reﬂected in the way the initial
PA colonisation is treated, which, based on molecular evidence, should be treated
intravenously right from the start and for prolonged periods.
WS16.4 Serum-betaglucan as marker to differentiate between fungal
airway colonization and infection in patients with cystic
ﬁbrosis
K. Ko¨tz1, A. Lindblad1. 1Sahlgrenska University Hospital, Pediatrics, CF-Center,
Queen Silvias Children Hospital, Gothenburg, Sweden
Objectives: Growth of fungi in cultures from airway secretions of CF patients
are difﬁcult to interpret since this can represent both colonisation and infection.
Betaglucan is an highly fungi-speciﬁc antigen, an elevated serum-concentration of
betaglucan (S-BG) is usually interpreted as sign for invasive fungal infection. To
investigate if S-BG can differentiate between fungal colonisation and infection in
CF patients.
Methods: S-BG, SR and CRP were analysed at the annual review. All airway
cultures during the last year, presence of ABPA and treatment with antimycotics
were reviewed.
Results: Until now, we analysed S-BG in 37 patients (1−17 yrs). S-BG was low (<60
pg/ml) in 23 patients (group 1, mean age 8.0 yrs), intermediate (60−80 pg/ml) in 5
(group 2, mean age 8.6 yrs) and pos (>80 pg/ml) in 9 (group 3, mean age 10.5 yrs).
No patient had signs of ongoing invasive fungal infection. In group 1, none had
growth of fungi in >50% of all cultures but 2 patients in group 2 (Exophiala,
Aspergillus) and 3 patients in group 3 (yeast, Exophiala). One patient in group 1
was treated with antimycotics, 1 in group 2 and 3 in group 3. There was one patient
with ABPA in group 2 and one in group 3. CRP and SR were normal in all except 2
patients. Mean FEV1% was 90% in group 1, 83% in group 2 and 81% in group 3.
Conclusion: Patients with elevated S-BG were older, more often on antimycotics,
had lower FEV1% and more positive cultures. An elevated S-BG did not automat-
ically indicate infection and a low S-BG did not rule out infection. This indicates
that S-BG only can function as a complementary marker to differentiate between
colonization and infection. The study is ongoing.
